Pulmonx Corporation (LUNG)
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.36 per share a year ago.
Pulmonx Corporation (LUNG) Q4 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q4 2024 Results Conference Call February 19, 2025 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President and Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jon Young - Canaccord Larry Biegelsen - Wells Fargo Joanne Wuensch - Citi Joseph Downing - Piper Sandler Operator Ladies and gentlemen, thank you for standing by. Welcome to Pulmonx Fourth Quarter 2024 Earnings Conference Call.
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.36 per share a year ago.
Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?
The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.
Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Elizabeth Sparicio - Investor Relations Steve Williamson - President & Chief Executive Officer Mehul Joshi - Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler John Young - Canaccord Frank Takkinen - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.43 per share a year ago.
Pulmonx: Low Bar For Q2 Earnings
New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses.
How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%
The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
